Compare Nasdaq100 ETF (QQQ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Sana Biotechnology Inc — how do they compare? Nasdaq100 ETF trades at $751.39 (market cap $506.92B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Nasdaq100 ETF is far larger — about 605.8× Sana Biotechnology Inc's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and Sana Biotechnology Inc for 23 Days on average.
| QQQ | SANA | |
|---|---|---|
Market Cap | $506.92B | $836.71M |
Volume | 48,326,518 | 4,507,444 |
52-Week High | $759.66 | $5.92 |
52-Week Low | $558.34 | $2.68 |
Typical Hold Time | 162 Days | 23 Days |
Sector | — | Health |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $750.47, down 0.96% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF faces mixed analyst sentiment with a 50/50 split between buy and sell recommendations. Recent news highlights QQQ's strong 10-year performance and ongoing innovation with new fund launches, though concerns about AI market valuations and interest rate impacts create headwinds.
The outlook remains cautiously optimistic given QQQ's tech-heavy exposure to AI growth trends, but elevated valuations and macroeconomic sensitivity present near-term risks. Long-term growth potential persists through innovation leadership, though investors should monitor concentration risk in technology holdings and market volatility around Fed policy decisions.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
